Pain and Inflammation Medications - Practice Flashcards
Pain and Inflammation Pharmacology – Comprehensive Notes
General approach and study tips (as emphasized in the session)
Start with ATI: use ATI as your primary textbook/resource; it has videos and rationale explanations. Review the first section on anatomy & physiology repeatedly to understand how medications work.
Use concept maps in small groups to organize information; highlight what’s most important and what could be life-saving (e.g., key adverse effects and patient teaching points). Colors and drawings help memory.
Pain assessment is best determined by the patient’s report on a standardized pain scale (before and after medication). Do not rely solely on vitals—combine patient report with behavior and vitals to judge effectiveness.
Pain and inflammation share mediators (e.g., prostaglandins, bradykinin, serotonin); inflammation adds white blood cell activity and vascular permeability (edema).
Be mindful of drug interactions, over-the-counter (OTC) products, and the need to tailor therapy to the individual (genetics, comorbidities).
Basic biology of pain and inflammation
Noxious stimuli cause release of mediators (e.g., prostaglandins, bradykinin, serotonin).
Mediators travel to the nervous system and brain where natural painkillers (endorphins) are released to diminish pain.
If pain persists, pharmacologic intervention may be needed:
Mild–moderate pain: peripheral-acting agents that act outside the CNS (often NSAIDs).
Moderate–severe pain: agents that act centrally or on opioid receptors in the CNS (opioids, some dual-mechanism drugs).
Inflammation involves white blood cells and vascular changes (edema due to increased vascular permeability).
Cortisol (steroids) normally suppresses inflammation through a negative feedback loop with the hypothalamic-pituitary-adrenal axis.
Pain assessment and nursing considerations
Always obtain a pain report from the patient (before and after analgesia).
Pain scales and rationale: use a standardized tool; document baseline and post-medication pain.
Additional indicators of efficacy include changes in body language, heart rate, blood pressure, and respiratory rate, but they are supplementary to patient report.
NCLEX-style questions often focus on applying these concepts to clinical scenarios.
COX inhibitors (NSAIDs)
NSAIDs are divided into two generations based on COX enzyme selectivity.
COX enzymes (cyclooxygenase):
COX-1: protective role in gastric mucosa, promotes platelet aggregation, supports kidney function.
COX-2: mainly involved in pain, inflammation, and fever.
First-generation NSAIDs (non-selective COX inhibitors)
Block both COX-1 and COX-2.
Common examples discussed: Aspirin and Ibuprofen; used for pain relief and anti-inflammatory effects.
Therapeutic effects: provide pain relief and decrease inflammation.
Key adverse effects and risks:
Gastric/ GI upset and ulcers (gastric mucosa protection is blocked via COX-1).
Kidney dysfunction (impaired renal prostaglandin synthesis can affect renal function).
Increased bleeding tendency due to impaired platelet aggregation (anticoagulant effects via COX-1 inhibition).
Important patient education for NSAIDs:
Watch for signs of GI bleeding: abnormal bruising, petechiae, dark or tarry stools, or coffee-ground emesis.
Monitor for changes in urine output and edema as signs of kidney dysfunction.
Bleeding risk signs beyond GI: easy bruising, prolonged bleeding from minor injuries.
Special notes:
Do not give aspirin to children with viral illnesses due to Reye syndrome risk (acute encephalopathy and liver dysfunction).
Prototype examples discussed: Aspirin (with some anticoagulation use) and Ibuprofen (pain relief; less bleeding risk than aspirin for long-term use).
Lab monitoring and teaching points:
Kidney function labs: BUN and creatinine.
Watch for and educate on GI bleeding signs.
Second-generation NSAIDs (COX-2 selective inhibitors)
More selective for COX-2, so fewer gastric/ulcer related side effects than first-generation NSAIDs.
However, they carry a higher risk of cardiovascular and cerebrovascular events due to their effect on platelet function and prostaglandin balance.
Common example discussed: Celecoxib (Celebrex).
Important patient education:
Report chest pain, sudden severe headache, or visual changes (signs of possible cardiovascular or cerebrovascular events).
Other notes:
Both generations are typically used for mild to moderate pain.
Monitor for CV symptoms and GI symptoms; weigh risk/benefit in patients with cardiovascular risk.
Dosing and patient safety points for NSAIDs
NSAIDs are often used for inflammation and pain; ensure appropriate patient selection, particularly with renal risk and GI risk.
Be mindful of drug interactions (e.g., other anticoagulants) and OTC NSAID use in combination with prescription NSAIDs.
Acetaminophen (Tylenol)
Mechanism: Central-acting analgesic and antipyretic with minimal anti-inflammatory effect (acts in CNS; limited peripheral anti-inflammatory action).
Uses: Pain and fever relief; not a strong anti-inflammatory agent.
Maximum safe dose: (4,000 mg/day).
Key safety concerns:
Hepatotoxicity with overdose or chronic high dosing; alcohol worsens liver injury risk.
Many OTC products contain acetaminophen; risk of unintentional overdose if combined with multiple acetaminophen-containing products.
Patient education:
Read OTC labels to avoid duplicating acetaminophen in combination products.
Watch for signs of liver injury: jaundice, abdominal pain, nausea/vomiting; labs include bilirubin, AST, ALT.
Antidote for overdose: Acetylcysteine (N-acetylcysteine).
Special notes:
Generally safer for children compared to NSAIDs, but still requires dosing accuracy and monitoring for liver effects.
Centrally acting non-opioids (dual mechanism)
Prototype: Tramadol.
Mechanism: Partial opioid receptor activity with inhibition of reuptake of norepinephrine and serotonin; central-acting.
Indication: Moderate to severe pain not adequately controlled by weaker analgesics.
Common adverse effects: Dizziness, nausea, urinary retention, sedation; can cause respiratory depression in some individuals.
Important precautions:
All individuals metabolize drugs differently; consider genetics and comorbidities.
Avoid driving or operating heavy machinery, especially at initiation or dose changes due to sedation risk.
Serious adverse effect: Risk of seizures in susceptible individuals.
Dosing caution: Use the smallest effective dose for the shortest possible duration; time to onset can be variable (often slower than pure opioids).
Opioid analgesics
Full opioid agonist (prototype: Morphine)
Primary receptor targets: Mu receptors.
Benefits: Very strong analgesia; mimics endogenous endorphins.
Common adverse effects: Respiratory depression, sedation, urinary retention, constipation; cough suppression (anti-tussive effect).
Safety considerations:
Higher risk in opioid-naive patients, the elderly, and those with reduced respiratory reserve (e.g., COPD, pneumonia).
Monitor respiratory status closely; be aware of signs of oversedation.
Antidote: Naloxone (Narcan).
Respiratory rate threshold: If respiratory rate < 12 breaths/min, prepare to administer naloxone.
Abuse and dependence: Potential for abuse, tolerance, and physical dependence; differ from addiction.
Opioid agonist-antagonist (prototype: Butorphanol or similar; transcript mentions both Pranolol and betorfanol as typographic variants)
Mechanism: Stimulates kappa receptors and blocks mu receptors.
Effects: Good analgesia but less euphoria than full agonists; can precipitate abstinence (withdrawal) in opioid-tolerant patients.
Contraindications: History of myocardial infarction (MI) or significant heart disease due to increased cardiac workload.
Withdrawal consequences: If patient has significant opioid exposure, can cause abstinence syndrome (withdrawal) with symptoms like sweating, tremors, anxiety, agitation, nausea, vomiting, diarrhea.
Important notes for practice:
If patient is opioid-tolerant or dependent, be cautious with agonist-antagonist due to precipitating withdrawal.
Monitor cardiovascular status and withdrawal symptoms if starting these agents.
Abstinence (withdrawal) timeline: Typically around after cessation or antagonist initiation (varies by patient and opioid history).
Naloxone (Narcan) – opioid antagonist
Role: Reverses opioid effects by blocking mu receptors in the CNS.
Important pharmacokinetic note: Naloxone has a shorter half-life than many opioids; repeated dosing may be required because opioids can outlast naloxone.
Potential withdrawal effects: Can resemble withdrawal: tachycardia, hypertension, tremors, agitation, nausea/vomiting; may cause transient increase in pain if opioid was treating it.
Patient management during reversal: If patient is awake, explain expected sensations and the potential return of pain; monitor vitals and respiratory status as the medication wears off or as opioid effect returns.
Allopurinol and gout management
Use: Long-term management of gout (hyperuricemia).
Mechanism: Reduces uric acid production; helps prevent urate crystal deposits in joints.
Hydration: Encourage high fluid intake; at least to promote uric acid excretion and prevent kidney stone or urate crystal deposition.
Adverse effects and safety concerns:
Hypersensitivity syndrome: rash, fever, oliguria, abdominal pain; can be serious and requires stopping the medication.
Long-term therapy may cause a metallic taste; this is usually temporary and can affect adherence.
Can cause nausea; taking with food can help.
Cataracts with long-term therapy; regular eye exams recommended.
Monitoring and efficacy:
Efficacy evidenced by decreased uric acid levels in the blood; monitor serum uric acid to assess response.
Prednisone and other corticosteroids
Role: Potent anti-inflammatory and immunosuppressive steroid.
Broad systemic effects due to non-selective action (not limited to inflammation):
Hyperglycemia, osteoporosis, GI ulcers, and Cushing’s syndrome with long-term use.
Other effects: altered fat distribution, sleep disturbance, memory/cognition changes, blood pressure changes.
Dosing and safety practices:
Use the lowest effective dose for the shortest duration possible to minimize systemic effects.
Must be tapered slowly when stopping to prevent adrenal insufficiency (the body’s own cortisol production after exogenous steroid withdrawal).
Patient education:
Monitor for signs of elevated blood sugar, infection, and take with food to reduce GI upset.
Do not abruptly discontinue after long-term use; follow taper schedule.
Practical safety and exam-focused points
Antidotes you should know by heart:
Acetaminophen overdose: Acetylcysteine.
Opioid overdose: Naloxone.
Learn the major adverse effects and the most common warning signs for each class to teach patients effectively (e.g., GI bleeding with NSAIDs; liver injury with acetaminophen; respiratory depression with opioids; hyperglycemia with steroids).
Understanding the role of each drug class helps you anticipate which patients will benefit and which are at risk (e.g., elderly patients with COX-2 inhibitors, patients with gout and hydration needs, patients with a history of ulcers).
Lab and diagnostic cues:
NSAIDs: monitor BUN and creatinine for kidney function; watch for GI symptoms that could indicate ulcers.
Acetaminophen: monitor liver enzymes (AST/ALT), bilirubin; check for signs of jaundice.
Allopurinol: monitor uric acid levels to gauge effectiveness; monitor for hypersensitivity symptoms.
Glucocorticoids: monitor glucose, signs of infection, GI symptoms; assess for Cushingoid features with long-term therapy.
Summary of key medications and quick facts (high-yield)
First-generation NSAIDs (non-selective COX inhibitors): Aspirin, Ibuprofen
Benefits: Pain relief; anti-inflammatory effects
Risks: GI ulcers, kidney dysfunction, bleeding; broader COX-1 inhibition
Important teaching: GI bleeding signs, kidney function labs; avoid aspirin in children with viral illnesses (Reye syndrome)
Second-generation NSAIDs (COX-2 selective): Celecoxib (Celebrex); others mentioned as prototypes
Benefits: Fewer GI side effects than first-gen
Risks: Cardiovascular and cerebrovascular events; inform patients about CV symptoms
Acetaminophen (Tylenol): Analgesic and antipyretic; no significant anti-inflammatory effect
Max dose: ; watch OTC combinations to avoid overdose
Liver risk; antidote: Acetylcysteine; avoid alcohol
Tramadol: Dual mechanism; central analgesic; slower onset; caution with driving; risk of seizures; variable response
Morphine (opioid full agonist): Strong analgesia via mu receptors; major risks include respiratory depression, constipation, urinary retention, sedation; antidote: Naloxone
Opioid agonist-antagonists (e.g., butorphanol-like agents): kappa agonist, mu antagonist; risk of withdrawal in opioid-dependent patients; contraindicated in patients with MI in some texts
Naloxone: Opioid antagonist; rapid reversal but short half-life; potential withdrawal symptoms; monitor for pain return and vitals
Allopurinol: Long-term gout management; hydrate well; watch for hypersensitivity syndrome; long-term risks include cataracts; measure uric acid levels to assess efficacy
Prednisone (glucocorticoid): Broad anti-inflammatory and immunosuppressive; taper slowly; monitor for hyperglycemia, osteoporosis, GI ulcers, Cushing’s features; watch for adrenal suppression and withdrawal risks
Optional practice prompts (to help study and prepare for questions)
If a patient presents with GI upset and history of ulcers, which NSAID class would be preferable and why?
How would you counsel a patient starting on Celecoxib about warning signs that require medical attention?
A patient on long-term prednisone suddenly stops taking it. What risk might occur, and how should you manage it?
A patient with gout wants to start allopurinol. What hydration instructions would you give and why?
A patient overdoses on acetaminophen. What is the antidote, and which lab tests would you expect to be abnormal?
In a patient with suspected opioid overdose, what is the appropriate rescue medication and what observations should guide repeated dosing?
Quick reference equations and numeric details (LaTeX format)
Maximum acetaminophen dose:
Withdrawal symptom time window for opioid antagonists:
Respiratory rate threshold prompting intervention: <
Hydration recommendation with allopurinol: at least
Dosing considerations and systemic effects are often summarized as: SS (short duration) and minimal effective dose for most patients; individualize by genetics and comorbidity.
If you’d like, I can convert these notes into a printable study sheet or create a set of flashcards keyed to specific medications and their adverse effects for quick review before exams.